Brief: Neurocrine Biosciences Initiates Phase 3 Registrational Program For NBI-1117568
30/04/2025 13:04
April 30 (Reuters) - Neurocrine Biosciences Inc NBIX.O: NEUROCRINE BIOSCIENCES INITIATES PHASE 3 REGISTRATIONAL PROGRAM FOR NBI-1117568 AS POTENTIAL TREATMENT FOR ADULTS WITH SCHIZOPHRENIA NEUROCRINE BIOSCIENCES INC - PHASE 3 STUDY TO ENROLL APPROXIMATELY 280 SCHIZOPHRENIA PATIENTS Source text: ID:nPn4rZbv4a Further company coverage: NBIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall